NDAINTRAVENOUSPOWDER
Approved
Oct 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
BORTEZOMIB (bortezomib) by Dr. Reddy's Laboratories is chymotrypsin-like activity of the 26s proteasome in mammalian cells. Approved for multiple myeloma, mantle cell lymphoma. First approved in 2019.
Drug data last refreshed 1w ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Bortezomib is a small-molecule proteasome inhibitor that blocks the 26S proteasome's chymotrypsin-like activity, preventing degradation of ubiquitinated proteins and triggering cancer cell death. It is approved for multiple myeloma and mantle cell lymphoma via intravenous administration. The mechanism disrupts intracellular homeostasis across multiple signaling cascades, making it effective against rapidly dividing hematopoietic tumor cells.
Peak
Product is at peak lifecycle stage with moderate competitive intensity (30/100), indicating stable market position and established brand infrastructure.
Mechanism of Action
chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitin-proteasome pathway plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining…
Indications (2)
Worked on BORTEZOMIB at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.